MedTrace Logo

Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants

NCT03076970 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2019-12-02

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, three-period, cross-over study to investigate the effect of sumatriptan (Imitrex) 100 mg on the pharmacodynamics and pharmacokinetics of lasmiditan 200 mg.

Conditions

Interventions

DRUG

lasmiditan 200 mg

drug including single placebo tablet

DRUG

Sumatriptan

drug including single placebo tablet

DRUG

matching placebo

single oral tablet -given with single lasmiditan tablet and with single sumatriptan tablet.

Sponsors & Collaborators

  • SNBL Clinical Pharmacology Center, Inc.

    collaborator INDUSTRY

  • CoLucid Pharmaceuticals

    collaborator INDUSTRY

  • Eli Lilly and Company

    lead INDUSTRY

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-21
Primary Completion
2017-04-13
Completion
2017-04-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03076970 on ClinicalTrials.gov